Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552326 · ClinicalTrials.gov registry record · Phase 3
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
A Phase 3 study of Severe Hypertriglyceridemia, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 446
- Enrollment target
- 20
- Study locations
NCT05552326: Completed Phase 3 study of Severe Hypertriglyceridemia, sponsored by Ionis Pharmaceuticals.
NCT05552326 is a Phase 3 study of Severe Hypertriglyceridemia that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 446 participants, above the 369-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05552326, a Phase 3 study of Severe Hypertriglyceridemia, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 446 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Olezarsen
Study Locations (20)
Florida
- Accel Research Sites - DeLand
- Finlay Medical Research - Greenacres City
- University of Florida Jacksonville - Jacksonville
- Meridien Research - Maitland
- Columbus Clinical Services - Miami
- Harmony Clinical Research, Inc - North Miami Beach
- Combined Research Orlando Phase I-IV - Orlando
- 3Sync Research - Sunrise
- R & B Medical Center LLC - Tampa
- JSV Clinical Research Study, Inc. - Tampa
- Metabolic Research Institute - West Palm Beach
Georgia
- Emory University - Atlanta
- Accel Clinical Research - Eatonton
- Northeast Georgia Medical Center - Gainesville
- Randomize Now - Newnan
Alabama
- Central Research Associates, Inc. - Birmingham
- Alabama Clinical Therapeutics, LLC Alabaster - Birmingham
Arizona
- Onyx Clinical Research - Peoria
California
- NRC Research Institute - Los Angeles
Indiana
- St. Vincent Medical Group - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2025-09-12 |
| Phase | Phase 3 |
What the finished NCT05552326 record still lists
NCT05552326 is an interventional study that assigns participants to a tested intervention. The registered 446 participants enrollment target is mid-sized for trials with a published cap, above the 369-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (21% higher).
The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05552326 names 20 study sites across 6 states, led by Florida, Georgia, Alabama.
Frequently Asked Questions
What is clinical trial NCT05552326 about?
NCT05552326 is a clinical study titled "A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia". The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
What is the current status of trial NCT05552326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 446 participants. The study started on 2022-08-31. Estimated completion is 2025-09-12.
What conditions does trial NCT05552326 study?
This clinical trial studies the following conditions: Severe Hypertriglyceridemia.
What interventions are being tested in trial NCT05552326?
The interventions under investigation include: Placebo (DRUG), Olezarsen (DRUG).
Who is sponsoring clinical trial NCT05552326?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05552326 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05552326's enrollment target sits among peer trials
446 3rd of 8 higher than 5 of 8 other Severe Hypertriglyceridemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
RECRUITING · Phase 3
-
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
ACTIVE NOT RECRUITING · Phase 3
-
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
- NCT04751435 · 445 participants · NA
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI